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estimated that more than 90% of 
people started on such treatment will 
not beneﬁ t. A 1% reduction in HbA1c 
would add only about 10 months 
of quality-adjusted life for a 45 year 
old and 6 weeks for a 75 year old. 
But such gains would be completely 
eliminated by any treatment deemed, 
by the patient, to reduce the quality of 
life by more than 3%, a ﬁ gure below 
that generally cited for injectable 
drugs. On this basis, even a drug for 
diabetes that improves cardiovascular 
outcomes might be a poor choice for 
many patients. 
These measures of likely health 
gains matter because such treatments, 
although potentially providing 
benefit in aggregate outcomes, are 
being used for individual benefit. 
The patient should be the one who 
makes choices about treatment once 
they are fully informed of potential 
beneﬁ ts, burdens, and harms. When 
these factors are closely balanced, 
and when patients vary in the weight 
they give to different factors, good 
quality information that is clearly 
communicated becomes particularly 
important. Data about glucose 
lowering falls far short of what 
licensing and regulatory bodies, 
clinicians, and patients need from new 
drugs for diabetes.
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and drugs of the previous century. We 
need a shift for tuberculosis: the one 
most important ingredient of a new 
paradigm is not biomedical or social, it 
is urgency.
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Calling tuberculosis a 
social disease—an 
excuse for complacency?
In the June 28 issue of The Lancet, 
Ali Mohsin re-discussed the paradigm 
of tuberculosis as a social disease.1 
The social element of tuberculosis 
is certainly important because there 
is strong evidence that tuberculosis 
does ﬂ ourish in poverty, but this has 
several pitfalls. First, reservation of 
an exceptional social disease status 
for tuberculosis might, paradoxically, 
be detrimental, especially if the 
designation social suggests that poverty 
eradication is necessary to eliminate 
tuberculosis. Second, a paucity of 
studies show that social interventions 
have an effect on tuberculosis 
transmission and incidence.2 Third, 
associating tuberculosis with poverty is 
a driver of stigma in communities.3
Is HIV any less social than tuberculosis? 
The HIV pandemic has taught us that 
with political will, adequate funding, 
community mobilisation, and scientiﬁ c 
resources, the huge barriers of poverty 
and social deprivation can be overcome. 
On the contrary, given the dismal 
success of eliminating tuberculosis, 
perhaps the biomedical community has 
used the social paradigm as an excuse to 
underperform. 
The emergence of drug-resistant 
tuberculosis is iatrogenic and suggests 
that the current biomedical and public 
health approaches for tuberculosis 
are failing. The time has come to use 
the successful HIV recipe (political 
will, money, activism, and brains) for 
tuberculosis. We have had enough 
of using the paradigms, diagnostics, 
Cardiovascular outcome 
trials of glucose-lowering 
strategies in type 2 
diabetes
We agree with Rury Holman and 
colleagues (June 07, p 2008)1 that 
prospective cardiovascular outcome 
studies of glucose-lowering drugs 
cannot solve the problem of how 
to help patients and clinicians make 
decisions. We support the authors’ 
proposal for exploitation of electronic 
health records to do large, low-cost, 
pragmatic randomised trials measuring 
real-world outcomes.2 These trials 
should be the standard for all newly 
licensed drugs.
These trials, however, will permit 
assessment of only previously 
licensed drugs. We have published 
an analysis,3 which suggests the 
need to rethink the criteria for 
approval, registration, and clinical 
use of new drugs. Even with 
optimistic assumptions, including 
cardiovascular benefit, we have 
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